Decoy Therapeutics (DCOY) Stock Price, News & Analysis

Company Overview

Decoy Therapeutics is a biotechnology company focused on developing antiviral medicines designed to mimic naturally occurring biological targets used by viruses to infect cells. Its approach is intended to create “decoy” molecules that bind to viruses and help prevent them from interacting with human cells.

The company’s research is centered on potential treatments for viral infections, including respiratory diseases. Its product candidates and development programs are based on proprietary decoy-protein technology, although detailed information about specific candidates, clinical-stage programs and commercial products is limited.

Decoy Therapeutics is headquartered in the United States and appears to be focused primarily on research and development rather than marketed products. Publicly available information about its operating history, geographic presence and leadership is limited.

Key Stats

• Today's Range: $3.05 to $3.41
• 50-Day Range: $2.56 to $5.30
• 52-Week Range: $2.18 to $55.92
• Volume: 421,844 shs
• Average Volume: 6.70 million shs
• Market Capitalization: $2.02 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $30.00
• Consensus Rating: Hold

Decoy Therapeutics Stock Analysis - MarketRank™

Decoy Therapeutics scored higher than 60% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Decoy Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Decoy Therapeutics has a consensus price target of $30.00, representing about 870.9% upside from its current price of $3.09.

Amount of Analyst Coverage

Decoy Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Decoy Therapeutics are expected to decrease in the coming year, from ($12.97) to ($19.33) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Decoy Therapeutics is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Decoy Therapeutics is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Decoy Therapeutics has a P/B Ratio of 0.28. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.64% of the float of Decoy Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Decoy Therapeutics has a short interest ratio ("days to cover") of 0.29, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Decoy Therapeutics has recently decreased by 19.57%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Decoy Therapeutics does not currently pay a dividend.

Dividend Growth

Decoy Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.26

News Sentiment

Decoy Therapeutics has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Decoy Therapeutics this week, compared to 2 articles on an average week.

Search Interest

2 people have searched for DCOY on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Decoy Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Decoy Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.50% of the stock of Decoy Therapeutics is held by insiders.

Percentage Held by Institutions

11.88% of the stock of Decoy Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 9/27/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:DCOY
• CIK: 1615219
• Web: www.decoytx.com
• Phone: (346) 772-0346
• Fax: N/A
• Employees: 11
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Decoy Therapeutics: $30.00
• High Price Target: $30.00
• Low Price Target: $30.00
• Potential Upside/Downside: +870.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($30.37)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12.52 million
• Net Margins: N/A
• Pretax Margin: -6,337.28%
• Return on Equity: -315.22%
• Return on Assets: -167.15%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.83
• Quick Ratio: 1.83

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $11.07 per share
• Price / Book: 0.28

Miscellaneous

• Outstanding Shares: 655,000
• Free Float: 645,000
• Market Cap: $2.02 million
• Optionable: N/A
• Beta: 0.56